These 3 posters covered the efficacy and safety of paliperidone palmitate in patients with schizophrenia.
News
From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.
What is new in research on attention-deficit/hyperactivity disorder?
Integrated models of care offer real time solutions by enabling primary care to identify and address behavioral health concerns through routine screening and early intervention more efficiently. Learn more here.
In honor of National Suicide Prevention Week next week, let’s talk about suicide.
Exploring the connection between trauma and the etiology of schizophrenia, and the ways this connection was historically interpreted in the case of the Genain quadruplets.
How can augmenting conventional antidepressants with creatine monohydrate help patients with depression?
Climate activism: how can you be involved as a mental health clinician?
The study explored the intervention’s effects using both quantitative and qualitative methods.
Check out this guide for supporting youth in their social media use.
The senior vice president of research at the American Foundation for Suicide Prevention offers thoughts on suicide and students.
The drug’s developers respond to the FDA’s decision to deny approval and consider future directions for this indication.
What is the association between cannabis use disorders and schizophrenia? Researchers used a nationwide register-based cohort study to investigate these associations.
Should everyone receive psychotherapy?
How is sailing similar to treating mood disorders?
In honor of Labor Day 2023, here are some recent expert discussions on burnout prevention as seen in Psychiatric Times®.
As we enter fall, we want to know what you're excited about in psychiatry!
From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.
What is new in research on transcranial magnetic stimulation?
The experts weighed in on a wide variety of psychiatric issues for the August 2023 issue of Psychiatric Times.
Celebrating 2 years of “Psychiatric Views on the Daily News”!
The treatment was well-tolerated, and no serious treatment-emergent adverse effects were identified.
Let us introduce you to the organization who wants to promote the professional development of psychiatrists as leaders.
Today is International Overdose Awareness Day!
Three eulogies for the Labor Day weekend.
A psychiatrist has an undeniable response to the Jacksonville shooting.
Let's think about the positives in psychiatry...
The funds will be distributed over the course of 5 years to support preclinical through phase 2 studies.
In this insightful interview, experts discuss the journey toward a more humanistic approach in psychiatry, the challenges of integrating biological and psychosocial aspects, and the need for comprehensive training for future psychiatrists.
Generics are now approved for adults in the treatment of BED and for individuals aged 6 years and older in the treatment of ADHD.
Advertisement
Advertisement
